Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Halozyme Therapeutics (DE:RV7)
FRANKFURT:RV7
Halozyme (RV7) Stock Price & Analysis
2 Followers
RV7 Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€30.78 - €50.40
Previous Close€49.75
Volume0.00
Average Volume (3M)85.00
Market Cap
€6.32B
Enterprise Value€7.39B
Total Cash (Recent Filing)$336.00M
Total Debt (Recent Filing)$1.50B
Price to Earnings (P/E)―
Beta0.63
Next Earnings
Aug 06, 2024EPS Estimate
€0.7Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding127,274,000
10 Day Avg. Volume9
30 Day Avg. Volume85
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)-8.14
Price to Sales (P/S)7.25
Price to Cash Flow (P/CF)16.00
P/FCF Ratio15.80
Enterprise Value/Market CapN/A
Enterprise Value/Revenue8.91
Enterprise Value/Gross Profit11.60
Enterprise Value/Ebitda16.28
Forecast
1Y Price Target
€53.02Price Target Upside6.57% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering9
Halozyme News
Bulls Say, Bears Say
Bulls Say
Patent ExtensionNew ENHANZE EU patent enables extension of higher, original royalty rate for subcutaneous DARZALEX.
Regulatory ApprovalEfgartigimod subcutaneous injection approved in China.
Revenue GrowthHalozyme is projecting to reach $1B in royalty revenues in 2027, with Wave 3 as a key driver on top of Wave 2 to achieve that mark.
Bears Say
Commercial RiskCommercial risk with respect to Enhanze, particularly in the multiple myeloma indication, which is dynamic and rapidly evolving.
Incremental RoyaltiesIncremental royalties from the improved subcutaneous nivo timeline are minimal.
Patent AssertionLaunch of SQ Keytruda may be needed for HALO to assert its patents.
---
Options Prices
Currently, No data available
---
Ownership Overview
0.00% Insiders
0.00% Mutual Funds
1.10% Other Institutional Investors
98.90% Public Companies and
Individual Investors
RV7 FAQ
What was Halozyme Therapeutics’s price range in the past 12 months?
Halozyme Therapeutics lowest stock price was €30.78 and its highest was €50.40 in the past 12 months.
What is Halozyme Therapeutics’s market cap?
Currently, no data Available
When is Halozyme Therapeutics’s upcoming earnings report date?
Halozyme Therapeutics’s upcoming earnings report date is Aug 06, 2024 which is in 10 days.
How were Halozyme Therapeutics’s earnings last quarter?
Halozyme Therapeutics released its earnings results on May 07, 2024. The company reported €0.725 earnings per share for the quarter, beating the consensus estimate of €0.631 by €0.095.
Is Halozyme Therapeutics overvalued?
According to Wall Street analysts Halozyme Therapeutics’s price is currently Undervalued.
Does Halozyme Therapeutics pay dividends?
Halozyme Therapeutics does not currently pay dividends.
What is Halozyme Therapeutics’s EPS estimate?
Halozyme Therapeutics’s EPS estimate is €0.7.
How many shares outstanding does Halozyme Therapeutics have?
Currently, no data Available
What happened to Halozyme Therapeutics’s price movement after its last earnings report?
Halozyme Therapeutics reported an EPS of €0.725 in its last earnings report, beating expectations of €0.631. Following the earnings report the stock price went up 3.653%.
Which hedge fund is a major shareholder of Halozyme Therapeutics?
Among the largest hedge funds holding Halozyme Therapeutics’s share is Fisher Asset Management LLC. It holds Halozyme Therapeutics’s shares valued at 11M.
---
Halozyme Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€53.02 (6.57% Upside)
€53.02 (6.57% Upside)
Blogger Sentiment
Bullish
DE:RV7 Sentiment 92%
Sector Average 72%
Sector Average 72%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
28.69%
12-Months-Change
Fundamentals
Return on Equity
261.68%
Trailing 12-Months
Asset Growth
8.36%
Trailing 12-Months
Company Description
Halozyme Therapeutics
Halozyme Therapeutics, Inc. is a biopharmaceutical company, which engages in research, development & commercialization of human enzymes and drug candidates. It focuses on novel oncology therapies that target the tumor microenvironment. Its products include PEGPH20, HTI-1511, PEG-ADA2, and HYLENEX recombinant. The company was founded by Gregory Ian Frost on February 26, 1998 and is headquartered in San Diego, CA.
---
RV7 Company Deck
---
RV7 Earnings Call
Q1 2024
0:00 / 0:00
---
RV7 Revenue Breakdown
54.01% Royalties
36.28% Product sales
9.71% Revenues under collaborative agreements
---
RV7 Stock 12 Month Forecast
Average Price Target
€53.02
▲(6.57% Upside)
Technical Analysis
Best Analysts Covering RV7
1 Year
1 Year Success Rate
11/12 ratings generated profit
1 Year Average Return
+31.71%
reiterated a buy rating 12 days ago
Copying Mitchell Kapoor's trades and holding each position for 1 Year would result in 91.67% of your transactions generating a profit, with an average return of +31.71% per trade.
---